CV301 and Anti-PD-1 Therapy in Non-Small Cell Lung Cancer

CV301 和抗 PD-1 治疗非小细胞肺癌

• 批准号: 10702747
• 负责人: Arun Rajan
• 金额: $ 0.99万
• 依托单位: DIVISION OF BASIC SCIENCES - NCI
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10702747
• 关键词: Adverse event; Antigens; Carcinoembryonic Antigen; Data; Disease; Dose; Enrollment; European; Evaluable Disease; Immune checkpoint inhibitor; Immunotherapy; Intercellular adhesion molecule 1; International; Journals; Leukocytes; Malignant Neoplasms; Manuscripts; Medical Oncology; Medical Societies; Modified Vaccinia Virus Ankara; Mucin 1 protein; Multicenter Studies; Nivolumab; Non-Small-Cell Lung Carcinoma; Patients; Platinum; Poxviridae; Publications; Radiology Specialty; Recurrence; Safety; Transgenes; anti-PD1 therapy; base; chemotherapy; cohort; meetings; pembrolizumab; posters; response; vector

CV301 consists of a poxvirus-based immunotherapy encoding transgenes for B7.1, intercellular adhesion molecule-1, leukocyte function-associated antigen-3, Carcinoembryonic Antigen and Mucin-1 based on a non-replicating Modified Vaccinia Ankara (MVA) vector. Five subjects with recurrent NSCLC following platinum-based chemotherapy have been treated with CV301 in combination with Nivolumab (four subjects) or pembrolizumab (one subject). Four patients are evaluable for response. One (25%) complete radiological response and three (75%) cases of disease stabilization have been observed. Treatment is well tolerated and the adverse event profile is similar to immune checkpoint inhibitor monotherapy. Overall, 12 patients have been enrolled in this multicenter study. The study has completed accrual and data are being prepared for publication. A poster based on this study was presented at the Annual Meeting of the European Society of Medical Oncology (ESMO) in November 2019. A manuscript related to the trial has been accepted for publication in the International Journal of Cancer.

CV301由基于B7.1，细胞间粘附分子-1，白细胞功能相关的抗原-3，Carcinoembryonic抗原和粘液蛋白-1的基于毒病毒的免疫疗法组成，基于非重新修饰的修饰疫苗Ankara（Mva）。基于铂基化学疗法后，有五名复发性NSCLC的受试者已与Nivolumab（四个受试者）或Pembrolizumab（一名受试者）结合使用CV301治疗。可以评估四名患者以进行反应。已经观察到1（25％）完全放射学反应和三例（75％）疾病稳定病例。治疗的耐受性良好，不良事件特征与免疫检查点抑制剂单一疗法相似。总体而言，这项多中心研究已入学12名患者。该研究已完成应计，并且正在准备数据供发布。基于这项研究的海报于2019年11月在欧洲医学肿瘤学学会（ESMO）年会上介绍。与该试验有关的手稿已被接受在《国际癌症杂志》上发表。